We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Scancell Holdings Plc | SCLP | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.175 | -1.77% | 9.70 | 16:35:11 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 9.875 | 9.875 | 9.875 | 9.70 | 9.875 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 09/5/2024 16:57 by inanaco efficacy ... investors look at the goal ... £1.5b market |
Posted at 09/5/2024 15:36 by nigelpm Frustrating for now investors come second but for the best long term returns this is the right strategy.It is IF they can continue to fund it. |
Posted at 05/5/2024 08:19 by marcusl2 British technology entrepreneurs and investors have long complained that America’s public markets offer more generous valuations and have a deeper pool of investors than the City of London. |
Posted at 02/5/2024 12:28 by inanaco so if your an investor with NO Knowledge you would apply the 3.4% success ratebecause you are looking at the sector not the individual Bio .... HIGH RISK ... this is why trinity values are so low ..... because of these risks % so those that consider it high risk are basically investors with little knowledge playing the numbers game Betting that one will make it ... hence they have a wide portfolio but as time goes on that portfolio will dwindle because of that 3.4% risk factor if they held you buy shares on a probability yet you don't trust probability as Bermuda said It cant be done .... love it ... |
Posted at 27/4/2024 20:17 by rogerbridge Could we agree on a score draw?Scancell over many years have promised deliver, long term investors are now sceptical after disapointments. Scancell, are now poised to deliver on more than one front. Personally, myself and some investors expect just that. |
Posted at 10/4/2024 22:07 by marcusl2 London markets are broken and closed, says pharma bossE-therapeutics joins the stampede of biotech companies quitting Aim James Titcomb 10 April 2024 • 6:49pm Ali Mortazavi Chief executive Ali Mortazivi says delisting the company comes with 'sadness and great worry' for UK markets A British pharmaceuticals company has criticised London’s stock markets for being “completely broken and closed” after announcing plans to de-list and pursue a potential flotation in New York. Ali Mortazavi, chief executive of E-therapeutics, said “urgent reform and action was needed” after accusing British investors of failing to back innovative companies. E-therapeutics said it would de-list, 17 years after floating on Aim, London’s junior market, as part of a £29m fundraising from existing investors. It said it would “explore the option of listing on [New York’s] Nasdaq in due course”. Writing on X, formerly Twitter, Mr Mortazavi said: “My overriding feeling in delisting [the company] is one of sadness and great worry. “To be clear, the UK markets are not just illiquid, they’re completely broken and closed. The situation is worse for small growth companies (in particular biotech) but even sizeable companies such as Shell and many others are saying the same thing.” |
Posted at 09/4/2024 09:58 by sci102 Open label and it's been 5 months since the last update. Previously they gave an update in September and then in November. They do have the data. Why they didn't present it at AACR when it was a golden opportunity is beyond me. I certainly don't think that they presented price sensitive and previously unannounced data at AACR, yet they did not RNS the update.The irony is they did RNS that they are attending all these conferences the past 2 months, but obviously they don't think the investors should know more than that. This is not a comment on regulatory requirements, it is about the stance of the company towards investors. |
Posted at 08/4/2024 07:12 by sci102 So once again scancell shows that something is not functioning properly with their IR team. Either they did not prepare the RNS beforehand so that it could be published this morning since they already knew what they were going to present OR decided again to leave investors in the dark whether they did present new data (that they surely have in their hands) or not.Again, this is not a comment on regulatory requirements, but about their stance towards investors. We will know the answer later today or tomorrow morning. |
Posted at 13/2/2024 18:27 by sci102 Not important in the grant scheme, but since the company used to give regular updates on scope, they should have given one at the previous presentation. And trust that at least their committed and experienced investors understand how clinical development works. Nobody that matters would care if for example at a particular snapshot the orr was 75% or whatever. Or at least they should realise that many would wonder about it in absence of updates anyway. No change of position from me, but I get why some opportunistic "casual" investors may be taking a step back. |
Posted at 01/12/2023 10:26 by bermudashorts SC102Redmile and Vulpes' contribution to the total amount raised was less than £3.5m. The placing has been priced at a level to attract sufficient funds from other investors to meet the total required. Given the fact that it was so heavily oversubscribed, you have to wonder whether they could have raised at a slightly higher level, but it's a balancing act. Price it too high and investors will walk away, too low and you have diluted more than you needed to. For sure though they will have sounded out the market in advance and set the price accordingly. The RNS this morning mentioned that new specialist life sciences investors had invested, hope we find out who they are as this will give some clue as to the direction of travel here. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
